Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsPaul Ridker, Charles H. Hennekens
Life of this patent
Estimating the term…
Abstract
The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.
Claims47
A method for characterizing an apparently healthy, nonsmoking individual's risk profile of developing a future myocardial infarction, comprising obtaining a level of a marker of systemic inflammation in the individual,
- comparing the level of the marker to a predetermined value, and
- characterizing the individual's risk profile of developing a future myocardial infarction based upon the level of the marker in comparison to the predetermined value.
A method for characterizing an individual's risk profile of developing a future cardiovascular disorder associated with atherosclerotic disease, other than fatal myocardial infarction, comprising
- obtaining a level of a marker of systemic inflammation in the individual,
- comparing the level of the marker to a predetermined value, and
- characterizing the individual's risk profile of developing said future cardiovascular disorder associated with atherosclerotic diseases other than fatal myocardial infarction, based upon the level of the marker in comparison to the predetermined level.
A method for characterizing an individual's risk profile of developing a future cardiovascular disorder associated with atherosclerotic disease, comprising
- obtaining a level of a marker of systemic inflammation in the individual,
- comparing the level of the marker to a first predetermined value to establish a first risk value,
- obtaining a level of a cholesterol in the individual,
- comparing the level of the cholesterol to a second predetermined value to establish a second risk value, and
- characterizing the individual's risk profile of developing the cardiovascular disorder based upon the combination of the first risk value and the second risk value, wherein the combination of the first risk value and second risk value establishes a third risk value different from said first and second risk values.
A method for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of an cardiovascular disorder associated with atherosclerotic disease, the agent selected from the group consisting of anti-inflammatory agents, anti-thrombotic agents, anti-platelet agents, fibrinolytic agents, lipid reducing agents, direct thrombin inhibitors, and glycoprotein II b/IIIa receptor inhibitors comprising:
- obtaining a level of a marker of systemic inflammation in the individual, and
- comparing the level of the marker to a predetermined value, wherein the level of the marker of systemic inflammation in comparison to the predetermined value is indicative of whether the individual will benefit from treatment with said agents.
Dependencies are inferred from the claim text.